Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB versus PONLIMSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB versus PONLIMSI.
BOSUTINIB vs PONLIMSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that inhibits the BCR-ABL kinase, including many imatinib-resistant mutations, and Src family kinases.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
400 mg orally once daily with food.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life approximately 33 hours (range 22-60 hr) after oral administration, supporting once-daily dosing.
Clinical Note
moderateBosutinib + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Bosutinib."
Clinical Note
moderateBosutinib + Digitoxin
"Bosutinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBosutinib + Deslanoside
"Bosutinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBosutinib + Acetyldigitoxin
"Bosutinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Primarily fecal (approx. 68% as unchanged drug and metabolites) and renal (approx. 25%, with <0.2% as unchanged drug in urine).
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor